the ribosome last year] and we've established the MRC firmly on the international health agenda."
Borys arrived at the MRC in 2007, with a Polish-tinged Welsh accent, warmth of manner, and almost boyish enthusiasm. The research council had just received fresh and contentious marching orders from the Cooksey Report (http://www. hm-treasury.gov.uk/cooksey_review_ index.htm). The report, prepared by venture capitalist David Cooksey for Gordon Brown, who was then Chancellor of the Exchequer (finance minister), called for the restructuring of British medical research to improve its contribution to the economy and to national healthcare.
The big quandary, from the government's perspective, was this: Britain has both the MRC, with 28 Nobel Prizes to its name, and the Wellcome Trust, the world's largest research charity, investing in biomedical research. It is also headquarters to several major pharmaceutical companies and has, in its National Health Service, potential for a unified database of more than 40 million patients. But its biotechnology sector has struggled to get off the ground. And with the US National Institutes of Health (NIH) spending $30 billion a year on biomedical research, compared with $5 billion (£3 billion) by the UK government and charities combined, it is not clear how the UK can stay fully competitive.
A full merger between the MRC and the NHS's National Institute for Health Research (NIHR) was considered and rejected by the Cooksey Report (much to the relief of basic researchers). Instead, significant extra resources (£300 million over 3 years) were allocated to the translation of research findings into healthcare, and a new Office for Strategic Coordination of Health Research (OSCHR) was established to coordinate the national effort.
The impact of these changes is already visible, including 78 new MRC awards for translational research, as well as the establishment of five general and seven specialized biomedical research centers for use by NIHR and MRC researchers at major British teaching hospitals. "These investments are giving us an infrastructure that MRC researchers can take advantage of," says Borysiewicz. "I think they've made remarkable progress, and just as remarkably, they are actually working together." The new arrangements are due to be reviewed in 2011 for their effectiveness in meeting the Cooksey Report's objectives.
"I think Borys has produced quite a significant cultural change at the MRC," says John Bell, Regius Professor of Medicine at the University of Oxford and chair of OSCHR. "He's made it much more outward looking, more part of the wider health research family." Basic research-
MRC Faces Rockier Road Ahead
The UK's Medical Research Council is losing a charismatic leader, who has worked hard to broaden the agency's remit and who will depart at a time of financial uncertainty for British research. ers at the MRC-concerned prior to Borys' appointment that the research council would close some intramural labs and move away from basic research-"have been reassured" by his tenure, Bell says. "The basic scientists have fallen in behind the new model. The reality is that some of the greatest beneficiaries of the new arrangements are basic scientists." Mark Walport, Director of the Wellcome Trust, agrees that Borysiewicz has successfully moved the MRC toward the translation agenda and says that fears that this would hurt basic research have proven to be "groundless."
Michael Schneider, an American molecular geneticist who moved to the UK National Heart and Lung Institute at Imperial College London from Baylor College of Medicine in Houston, Texas in 2007 and sits on the MRC Council, says that these changes are making a big difference at Imperial. Since October 2007, for example, Imperial, like most major US medical schools (with the exceptions of Baylor and Harvard), has been running its own hospitals through the Imperial College Healthcare NHS Trust. Schneider says that the new arrangement has made it easier for biologists and other laboratory scientists at Imperial to address medical questions, working with clinicians at world-famous London hospitals in the Trust, such as Charing Cross, Hammersmith, and St. Mary's. "Our scientists are very motivated to have their work applied to biomedical problems," he says, "but this involves a dialogue that doesn't always happen spontaneously." Schneider adds that despite the US advantage of scale, the UK can excel through the quality of its institutions and the advantages of working with the NHS.
Ninety percent of the Cooksey objectives have been met, Borysiewicz contends, with most of the outstanding issues related to informatics-the quest to integrate National Health Service patient records into a single research database. He notes that while the NHS has developed a single health records system in Scotland, the much larger English system remains fragmented.
Borysiewicz's tenure has also been marked by efforts to broaden MRC's international remit, both in terms of more collaborations with partners overseas and in addressing global health issues, such as infectious diseases. He's especially proud, for example, of a new joint initiative involving France and Germany (and other European Union member states) on research into Alzheimer's disease, dementia, and other neurodegenerative conditions (http:// europa.eu/rapid/ pressReleasesAction. do? reference=IP/09/1171&format=HT). "An analysis between the three countries showed that there was immense complementarity between skills in this field in Britain, France and Germany," he says. "That is now being used as a pilot to see if this approach to funding will work. At the moment, its 30 million euros and we're looking to it to be far larger in due course."
Additionally, the MRC has been engaged in an ambitious program to rebuild its largest intramural laboratories. Work started in summer 2008 on the construction of a new, £200 million facility in Cambridge that will house the 400 researchers at perhaps MRC's most famous institute, the Laboratory of Molecular Biology. And the agency is working with the Wellcome Trust, Cancer Research UK, and University College London to build a UK Centre for Medical Research and Innovation (UKCMRI) in central London, which would house up to 1500 staff with the goal of becoming Europe's premier biomedical research facility.
UKCMRI was announced by Gordon Brown in December 2007 and is due to open in 2014, but construction work has yet to begin, and with Britain's public finances in crisis, doubts persist that the £500 million project will see the light of day. Borysiewicz says he is "very confident" that the mammoth project will proceed even if, as is widely expected, a Conservative government gets elected this year. "I believe, from the conversations I've had, that they are very supportive of the project," he says. "But we'll have to wait and see."
Another critical issue for the MRC is its position relative to the Wellcome Trust, the UK charity whose £590 million annual budget almost matches the MRC's £720 million. (In the United States, by contrast, the largest philanthropic organization, the Howard Hughes Medical Institute, spent $700 million last year on research, less than one-fortieth of the NIH budget.)
Pressed by researchers at the Edinburgh meeting in December last year, Borysiewicz conceded that Wellcome's November 2009 announcement that it will concentrate its support on 7 year "investigator awards" to a smaller number of exceptional researchers could intensify demands on MRC's own grants (http://w w w.wellcome.ac.uk /News/ Media-of fice/Press-releases/2009/ WTX057403.htm). "You're going to see a greater push from young investigators, who need our grants before they can apply for £1 million from Wellcome," Borysiewicz said. "So I see us being put under more pressure, at a time when we won't have much financial leeway." Wellcome Trust's Walport denies that this will occur. "We support very good people and we'll continue to do that," he says. "I'm not convinced that [the change] will put more pressure on the MRC."
Another important issue for the MRC is the future of its London headquarters, and the associated issue of autonomy. At the end of this year, the lease expires on its imposing Georgian abode in central London. This coincides with powerful pressure from the government to relocate with the other six UK research councils to a dismal campus in Swindon, 80 miles west of London. At the end of last year, Borysiewicz agreed to a compromise with the Department for Business, Innovation and Skills (BIS) that will, he says, keep 90-100 senior staff at a new location in London, with another 120 moving to Swindon. Observers say that the split is the best outcome that the MRC could have hoped for but will nonetheless damage staff morale. "It's going to weaken the MRC a lot," says one official, who knows the research council well. The move also carries overtones of the recurrent threat that the MRC, which is due to celebrate its centenary in 2013, might conceivably be merged with the other research councils in a bid to rationalize operations. "I think it is unlikely to happen," says Borysiewicz. "But you can't discount it altogether." All of this takes place against a backdrop of sharply deteriorating public finances in Britain. The general view is that research funding-after doubling over the last 10 years-will now face cuts of 10% or more over the next 2 or 3 years, probably under an emer-gency budget that is expected to be announced by the winner of the general election, which is likely to be in May. What happens when these cuts emerge remains "open to question," says Bell, whose OSCHR office is already coordinating a March budget submission for this year's Comprehensive Spending Review, which sets UK government spending plans every 3 years. Bell thinks he might be asked to repeat the exercise after the election. "It may be that some sections of science will be largely protected" from the anticipated cuts, Bell says, and even if they aren't, "we can continue to be pretty successful, provided that any contraction is organized in ways that won't damage the entire medical research enterprise."
In a relatively short time at the MRC, most observers agree, Borysiewicz has succeeded in starting to build the stronger partnerships demanded by the Cooksey Report, to nurture the translation of research results into healthcare. As Walport puts it: "He's demonstrated that they can support both basic science and clinical research." "Borys will be missed for his impeccable scientific taste and for his immense personal and political skills," says Schneider. "He's also had the good fortune to come into the MRC at a very dynamic time. I'd be worried about replacing him in any circumstances, and it'll be even more of a challenge now, given the funding outlook. That being said, the MRC has been around for almost 100 years, and I'm sure it can attract a toprate individual to lead it."
